Replies to post #11827 on GTC Biotherapeutics (fka GTCB)

[gym gravity]

"I don't know if there have been any sales of ATryn, has there?"

in the last cc transcript:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29148987

During this second quarter, we anticipate in excess of $7 million in cash receipts from our external programs and from the sale of product to LEO, which was manufactured in Q4 and Q1. This should significantly reduce the net cash used in the second quarter. We project the net cash use for the remainder of 2008 in the range of $17 million to $19 million, which is consistent with our previous guidance [#msg-29133935]. Importantly, any upfront payments from new partnering agreements would further reduce the net cash use forecasted for 2008.

[vinmantoo]

<The EMEA barely approved ATryn, and then only after Genzyme intervened. I don't know if there have been any sales of ATryn, has there? Because at least if there has been sales that is some form of data that will reassure the FDA. >

John,

Why do you need to lie? The EMEA was going to exclude some patients from the data after the study had been completed even after the EMEA had already said those patients would be included. GTCB appealed to have all the patients included as the EMEA originally agreed. The experts on the CHMP review board agreed with GTCB so all the patients were included. You are purposely mispresenting the facts by suggesting it was a legal manuever that required the intervention of Genzyme and it is sickening to me, though not as much as watching the GTCB price come down.